Clinical trials: Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Alzheimer Disease or Associated Disorder, Mild to Moderately Severe Dementia
Effectiveness of Care Management in Alzheimer Patients
Context: The French Alzheimer plan 2008-2012 includes the implementation of "disease managers" or social workers, from the onset of the disease, for every patient with a diagnosis of Alzheimer disease or associated disorder.
- Trial name
- AIDALZ (NCT01081743)
- Testing
- Intervention of the social worker
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Institut de Sante Publique, d'Epidemiologie et de Developpement
Alzheimer Disease
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for…
- Trial name
- NCT03539380
- Testing
- TRx0237
- Sponsor
- TauRx Therapeutics Ltd
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Mild Dementia, Moderate Dementia
Touchscreen Technology and Art for People With Dementia in Care Homes
The prevalence of dementia is rapidly growing worldwide, affecting 46.8 million people in 2015. The 2014 Alzheimer's Society report estimated that 311,730 people with dementia were living in care homes in the United Kingdom (UK).
- Trial name
- NCT03773016
- Testing
- Art apps
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Alzheimer Disease
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to…
- Trial name
- NCT00297362
- Testing
- Galantamine hydrobromide
- Volunteers
- 344 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Alzheimer's Disease
Double Blind Study of Trp01 in Patients With Alzheimer's Disease
The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT00202124
- Testing
- Tryptophan
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Queen's University
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
OmegAD (Omega-3 and Alzheimer's Disease)
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA.
- Trial name
- NCT00211159
- Testing
- EPAX 1050TG
- Where
- Sweden
- Volunteers
- 204 people
- Sponsor
- Karolinska University Hospital
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet